Pfizer Ltd. Technical Momentum Shifts to Mildly Bullish Amid Mixed Indicators

Technical Trend and Price Movement Overview

Pfizer’s current market price stands at ₹4,864.80, down 1.03% from the previous close of ₹4,915.45. The stock’s intraday range today fluctuated between ₹4,810.80 and ₹4,914.00, remaining below its 52-week high of ₹5,878.55 but comfortably above the 52-week low of ₹4,361.00. This price action reflects a consolidation phase with mild bearish pressure on the daily timeframe, as indicated by the mildly bearish daily moving averages.

However, the broader technical trend has shifted from a sideways pattern to mildly bullish, particularly on the weekly charts. This suggests that while short-term price action may be subdued, the medium-term outlook is improving, supported by several momentum indicators.

MACD and Momentum Oscillators

The Moving Average Convergence Divergence (MACD) indicator presents a mixed signal. On the weekly scale, the MACD is mildly bullish, indicating that momentum is gradually improving and the stock could be entering a phase of upward price movement. Conversely, the monthly MACD remains mildly bearish, signalling that longer-term momentum has yet to fully confirm a sustained uptrend.

The Know Sure Thing (KST) oscillator aligns with this duality, showing mild bullishness on the weekly timeframe but mild bearishness monthly. This divergence between short- and long-term momentum oscillators suggests that investors should monitor the stock closely for confirmation of a sustained trend reversal.

Relative Strength Index (RSI) and Bollinger Bands

The RSI readings on both weekly and monthly charts currently provide no clear signal, hovering in neutral territory. This indicates that the stock is neither overbought nor oversold, offering a balanced risk profile for traders considering entry or exit points.

Meanwhile, Bollinger Bands on both weekly and monthly timeframes are bullish, suggesting that volatility is expanding in a positive direction. The stock price is likely testing the upper bands, which often precedes a breakout or continuation of an upward trend. This technical setup supports the mildly bullish weekly trend and hints at potential upside momentum if confirmed by other indicators.

Moving Averages and Volume-Based Indicators

Daily moving averages remain mildly bearish, reflecting recent price softness. This short-term weakness could be a result of profit-taking or market consolidation after recent gains. However, volume-based indicators such as On-Balance Volume (OBV) are mildly bullish on both weekly and monthly charts, signalling that buying interest is gradually increasing despite the recent price dip.

Additionally, the Dow Theory assessment is mildly bullish on both weekly and monthly scales, reinforcing the notion that the stock is in the early stages of a positive trend development. This is a critical confirmation for investors looking for technical validation before committing capital.

Comparative Returns and Market Context

Pfizer Ltd.’s recent returns show a mixed but generally resilient performance relative to the Sensex benchmark. Over the past week, the stock has outperformed the Sensex with a 3.38% gain compared to the index’s 2.17%. The one-month return is even more impressive at 6.56%, significantly ahead of the Sensex’s 0.86% rise.

Year-to-date, Pfizer has declined by 2.36%, which is better than the Sensex’s 7.97% fall, indicating relative strength amid broader market weakness. Over the one-year horizon, the stock’s return of -2.81% slightly outperforms the Sensex’s -3.20%. The three-year return of 23.00% also surpasses the Sensex’s 19.34%, highlighting Pfizer’s ability to generate superior gains over the medium term.

However, the five-year return of -17.66% lags the Sensex’s robust 44.25% gain, reflecting challenges faced by the company or sector during that period. The ten-year return of 149.85% remains strong but still trails the Sensex’s 182.99%, underscoring the importance of sector and company-specific factors in long-term performance.

Mojo Score Upgrade and Analyst Sentiment

MarketsMOJO has upgraded Pfizer Ltd.’s Mojo Grade from Sell to Hold as of 03 Aug 2026, reflecting improved technical and fundamental outlooks. The current Mojo Score stands at 54.0, indicating a neutral stance with potential for upside if momentum sustains. The small-cap status of the company adds an element of volatility but also opportunity for growth-oriented investors.

This upgrade aligns with the mildly bullish weekly technical trend and positive volume indicators, suggesting that the stock is stabilising and may be poised for a gradual recovery. Investors should weigh this against the mildly bearish monthly MACD and moving averages, which counsel caution and the need for confirmation.

Investor Takeaway and Outlook

Pfizer Ltd.’s technical landscape is characterised by a cautious but improving momentum profile. The shift from sideways to mildly bullish weekly trends, supported by bullish Bollinger Bands and positive volume indicators, suggests that the stock is regaining investor interest. However, the mildly bearish monthly MACD and daily moving averages indicate that the longer-term trend remains under pressure, requiring further confirmation before a decisive uptrend can be declared.

Investors should consider Pfizer’s relative outperformance against the Sensex in recent weeks and months as a positive sign, while remaining mindful of the stock’s small-cap volatility and sector-specific risks. The recent upgrade to a Hold rating by MarketsMOJO reflects this balanced view, recommending a watchful stance rather than aggressive accumulation at this stage.

Technical traders may find opportunities in the mildly bullish weekly signals, particularly if the stock breaks above resistance levels near the recent highs. Conversely, cautious investors might wait for clearer confirmation from monthly indicators and moving averages before increasing exposure.

Overall, Pfizer Ltd. presents a nuanced technical picture with early signs of momentum improvement tempered by longer-term caution. This makes it a stock to monitor closely for shifts in trend confirmation and volume dynamics in the coming weeks.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →